Financial Performance - Operating revenue for the first quarter reached CNY 516,817,163.09, an increase of 83.61% year-on-year[4] - Net profit attributable to shareholders was CNY 5,141,403.06, a turnaround from a loss of CNY 25,032,741.60 in the same period last year[4] - The company reported a basic earnings per share of CNY 0.03, compared to a loss of CNY 0.12 per share in the same period last year[4] - The weighted average return on equity improved to 0.34% from -1.70% year-on-year[4] Cash Flow - Cash flow from operating activities improved significantly, with a net cash flow of -CNY 11,996,421.08, up 84.92% from -CNY 79,571,848.31 year-on-year[4] - The net cash flow from operating activities improved to -RMB 11,996,421.08 in Q1 2021, a positive change of 84.92% compared to -RMB 79,571,848.31 in Q1 2020, indicating better cash collection[12] - The company’s cash flow from financing activities decreased to RMB 36,667,810.27, down 83.04% from RMB 216,246,678.06 in Q1 2020, primarily due to reduced government financing support related to the pandemic[12] Revenue Growth - The SPD business achieved a revenue growth of 189.25% compared to the previous year[7] - The company's revenue for Q1 2021 reached RMB 516,817,163.09, representing an increase of 83.61% compared to RMB 281,472,317.63 in Q1 2020, primarily due to the impact of the pandemic in the previous year[11] Operating Costs and Expenses - Operating costs for Q1 2021 were RMB 402,882,148.05, up 80.41% from RMB 223,319,689.52 in Q1 2020, driven by revenue growth[11] - R&D expenses surged to RMB 9,603,868.15, a significant increase of 930.75% from RMB 931,740.33 in Q1 2020, reflecting ongoing investments in information technology and product development[11] - The company reported a significant decrease in operating expenses, with a drop of 96.06% in non-operating expenses to RMB 433,142.58, compared to RMB 10,994,184.16 in Q1 2020, due to reduced donations for pandemic relief[12] Assets and Liabilities - Total assets increased by 3.12% to CNY 4,028,170,359.41 compared to the end of the previous year[4] - Total long-term borrowings increased to RMB 353,900,000.00, a rise of 39.20% from RMB 254,246,969.72 at the end of 2020, due to adjustments in the company's financing structure[11] Shareholder Information - The total number of shareholders reached 10,976 by the end of the reporting period[9] Government Support - The company received government subsidies amounting to CNY 2,480,390.50 related to production and research and development during the reporting period[7] - The company received other income of RMB 2,480,390.50, a substantial increase of 987.89% from RMB 228,000.00 in Q1 2020, mainly from production and R&D incentives[11] Regional Performance - The proportion of revenue from Wuhan, which was significantly impacted by COVID-19 last year, decreased by 56.99% in the previous year but has since recovered[7]
塞力医疗(603716) - 2021 Q1 - 季度财报